- ACT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $620.8 million.
- ACT is up 3% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ACT with the Ticky from Trade-Ideas. See the FREE profile for ACT NOW at Trade-Ideas More details on ACT: Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. ACT has a PE ratio of 335.5. Currently there are 16 analysts that rate Actavis a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Actavis has been 2.5 million shares per day over the past 30 days. Actavis has a market cap of $57.6 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.35 and a short float of 10.1% with 0.81 days to cover. Shares are up 32.8% year-to-date as of the close of trading on Tuesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.